U.S. markets close in 11 minutes
  • S&P 500

    3,812.16
    -9.39 (-0.25%)
     
  • Dow 30

    30,980.26
    +33.27 (+0.11%)
     
  • Nasdaq

    11,154.88
    -26.66 (-0.24%)
     
  • Russell 2000

    1,715.03
    -23.82 (-1.37%)
     
  • Crude Oil

    109.41
    -2.35 (-2.10%)
     
  • Gold

    1,820.10
    -1.10 (-0.06%)
     
  • Silver

    20.76
    -0.11 (-0.54%)
     
  • EUR/USD

    1.0443
    -0.0082 (-0.78%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • GBP/USD

    1.2117
    -0.0067 (-0.55%)
     
  • USD/JPY

    136.5490
    +0.4210 (+0.31%)
     
  • BTC-USD

    20,099.94
    -190.83 (-0.94%)
     
  • CMC Crypto 200

    433.44
    -6.22 (-1.42%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

RVL Pharmaceuticals plc to Present at Upcoming Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
RVL Pharmaceuticals plc
RVL Pharmaceuticals plc

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:

H.C. Wainwright Global Investment Conference, Miami Beach, FL

Date:

Tuesday, May 24, 2022

Time:

11:00 a.m. ET

Webcast:

Click Here


Jefferies Healthcare Conference, New York City, NY

Date:

Thursday, June 9, 2022

Time:

1:30 p.m. ET

Webcast:

Click Here

The webcasts will be available thereafter via the Company’s website www.rvlpharma.com website under the “Investor & News” section.

About RVL Pharmaceuticals plc

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Investor and Media Relations for RVL Pharmaceuticals plc

Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com